| Ms Daphne M Burnett, DNP,APRN,FNP-C,CCNS | |
|
1900 South Country Club, El Reno, OK 73036 | |
| (405) 295-2900 | |
| (405) 350-3744 |
| Full Name | Ms Daphne M Burnett |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1900 South Country Club, El Reno, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952713745 | NPI | - | NPPES |
| Entity Name | Healthcare One Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174811368 PECOS PAC ID: 4688848369 Enrollment ID: O20111115000073 |
News Archive
Provectus Pharmaceuticals announced today that it has obtained final clearance to begin the first Phase 1 clinical trial of PV-10, the Company's lead cancer treatment.
New research from the U.S. has shed a light on why many night and early morning shift workers have problems sleeping.
Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Daphne M Burnett, DNP,APRN,FNP-C,CCNS 4012 Tori Place, Yukon, OK 73099 Ph: (405) 471-7418 | Ms Daphne M Burnett, DNP,APRN,FNP-C,CCNS 1900 South Country Club, El Reno, OK 73036 Ph: (405) 295-2900 |
News Archive
Provectus Pharmaceuticals announced today that it has obtained final clearance to begin the first Phase 1 clinical trial of PV-10, the Company's lead cancer treatment.
New research from the U.S. has shed a light on why many night and early morning shift workers have problems sleeping.
Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion.
› Verified 2 days ago
Ann Maureen Burkle Robison, APRN CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1900 S Country Club Rd, El Reno, OK 73036 Phone: 405-295-2900 Fax: 405-295-2905 | |
Allison Diane Henrichs, NURSE PRACTITIONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1900 S Country Club Rd, El Reno, OK 73036 Phone: 405-295-2900 Fax: 405-295-2905 | |
Kristi Little, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1900 S Country Club Rd, El Reno, OK 73036 Phone: 405-295-2900 | |
Alana Christine Mckinney, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 19400 Sw 44th St, El Reno, OK 73036 Phone: 405-414-4383 | |
Darcy White, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1900 S Country Club Rd, El Reno, OK 73036 Phone: 405-295-2900 | |
Angela Upton, APRN-CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1900 S Country Club Rd, El Reno, OK 73036 Phone: 405-295-2900 Fax: 405-295-2905 | |
Sarah Kelleen Menz, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2005 Parkview Dr Ste 2, El Reno, OK 73036 Phone: 405-776-1465 Fax: 405-869-7779 |